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EDITORIAL
Adjuvant chemotherapy for
colorectal cancer 
In the last decade, adjuvant chemotherapy for colorectal cancer
has become an established component of clinical management.
However, considerable controversy still surrounds its application
in some patient groups within this population. The original data
which changed practice in the USA were based on 2 trials, the
original small NCCTG trial (Laurie et al, 1989) and the subsequent
confirmatory intergroup study which was updated in 1995
(Moertel et al, 1995) demonstrating increased survival from a dose
intensive 12 month 5-fluorouracil plus levamisole adjuvant
therapy. This led to the NIH consensus statement in 1991, which
mandated adjuvant 5FU and levamisole for Dukes C colon cancer
in the USA. As a result, other ongoing trials in the USA were
discontinued. Subsequently, data from the pooled analysis of 3
smaller (IMPACT, 1995) and the results of 2 prematurely closed
trials (Francini et al, 1994; O’Connell et al, 1997) following the
NIH consensus statement have also confirmed the benefits of 5FU
in addition to folinic acid over 6 months as effective adjuvant
therapy. A meta-analysis of the whole dataset of adjuvant 5FU-
based therapy in colorectal cancer estimated the survival benefit to
be about 6% (NHS Executive, 1997). 
Results from trials comparing surgery plus chemotherapy
versus surgery alone remain of particular value in providing
further clarification to persisting areas of uncertainty. In this issue,
the mature results of the Dutch adjuvant chemotherapy study using
5FU plus levamisole are published (Taal et al, 2001). This study
was also prematurely closed in February 1996 in light of the accu-
mulating published data, when 1029 of a planned 2000 patients
had been recruited. In the whole group, at nearly 5 years median
follow-up, overall survival was improved by the addition of
chemotherapy from 55% to 65% (P = 0.007). In node-positive
patients the absolute improvement was 12% (44% v 56%). When
we discuss the role of adjuvant chemotherapy with our patients,
how do we explain to them the degree of benefit that this long and
relatively onerous treatment will bring them? How do we help
those come to a decision for whom both we, as oncologists and
they, as the patients, are uncertain of the relative merits of treat-
ment? What data are in our mind and perhaps in our explanations
as we talk to the elderly person in whom other causes of death
compete with the risk of recurrence of their carcinoma? Clear data
regarding the size of the benefit are important. Is it 6% as the meta-
analysis indicates or nearer 12% improvement in survival as the
Dutch and IMPACT studies suggest? Given that the meta-analysis
included all trials including those with sub-optimal chemotherapy
regimens, it is probable that the benefit from now current standard
5FU and folinic acid regimens is nearer 12% than 6%. 
The effect of adjuvant chemotherapy for node-negative (stage
II) patients remains controversial. In the Dutch study 468 patients
were stage II and these showed a similar benefit to the stage III
patients with an improved relative survival of 78% versus 70%.
These data need to be seen in the light of pooled results from
American and European studies in this patient group. In a report of
1565 stage II colon cancer patients from the series of NSABP
trials, an equivalent benefit was demonstrated as for the stage III
patients with a mortality reduction of 30% for the more active
adjuvant therapy (Mamounas et al, 1999). In contrast, 1016 stage
II patients entered into 5 separate trials of 5FU plus folinic acid
versus observation showed no significant increase in event-free or
overall survival at 5 years (Impact B2, 1999). Further data will be
forthcoming from the QUASAR trial of over 2000 patients of
whom about 80% are node-negative. The current view is that there
is little biological difference between node-negative and node-
positive cancers and that chemotherapy has a proportionately
similar effect in the 2 settings. Because of the smaller overall risk
for patients with node-negative cancers, the absolute benefit is
smaller. Patients with node-negative disease should be referred to
oncologists for discussion about these issues so that the patients
may participate in the decision to receive adjuvant therapy. Ideally
they should continue to be entered into trials with a no treatment
arm, though it is becoming increasingly difficult to obtain
informed consent to this randomisation in my experience. 
Rectal cancer is an even greater minefield. Because of the
concomitant usage of radiotherapy in many patients with rectal
cancer, the effect of adjuvant chemotherapy per se is very difficult
to determine. In addition, the marked reduction in local recurrence
that has occurred with the widespread adoption of total mesorectal
excision in some European countries has raised questions about
how this will effect benefits from adjuvant therapy. Combined
chemotherapy and radiotherapy has been associated with a
survival benefit in patients with Dukes B and C rectal cancer,
when compared with radiotherapy alone (Krook et al, 1991). One
meta-analysis of adjuvant chemotherapy of colorectal cancer
(Dube et al, 1997) showed a greater benefit for rectal cancer than
for colon cancer (OR for mortality 0.64, 95% CI 0.48–0.85) and
estimated the size of benefit to be a 9% increase in survival for
rectal cancer patients. NSABP R-02 evaluated chemotherapy with
or without post-operative radiotherapy and showed no advantage
for survival in adding radiotherapy to adjuvant chemotherapy,
but did show an advantage for those randomised to 5FU and
folinic acid rather than the alternative schedule (Wolmark et al,
2000). The Dutch study shows that although the effect of adjuvant
chemotherapy in rectal cancer was in the same direction as for
colon cancer, this did not achieve significance. This negative result
must be viewed with caution. Only 299 patients with rectal cancer
were entered, half of whom also received radiotherapy. The tests
for interaction show no significant heterogeneity, suggesting there
was not a qualitatively different phenomenon occurring in the
rectal cancer patients. Currently, there is little enthusiasm from
patients or oncologists to randomise node-positive rectal cancer
patients into surgery-only protocols. Further analysis of all patients
entered into randomised trials with a chemotherapy comparison in
rectal cancer will clarify this area. 
There remain a number of very important questions to be
addressed in the adjuvant therapy of colorectal cancer. Treatment
regimens are changing. 5FU and levamisole is no longer consid-
ered the standard. Equivalent benefits can be obtained with 6
months therapy with 5FU and folinic acid (Haller et al, 1998). The
QUASAR trial has confirmed that the addition of levamisole to
5FU and folinic acid brings no further benefit and that low-dose
folinic acid is as effective as high-dose (QUASAR, 2000a). In a
non-randomised comparison, including nearly 5000 patients that
trial also showed that weekly injections rather than 5 times weekly
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is as effective with much-reduced toxicity (QUASAR, 2000b).
Trials currently underway will provide data on the additional
benefit of irinotecan and oxaliplatin in combination with 5FU and
folinic acid. Usage of oral fluoropyrimidines in the adjuvant
setting has already been proven in Japan (Sakamoto et al, 1999)
and is under further evaluation in the West. Combinations of oral
fluoropyrimidines plus irinotecan or oxaliplatin also need to be
evaluated. In the UK, a large trial of cyclo-oxygenase II-selective
inhibition, following completion of all standard therapy has just
commenced. In due course there will be trials evaluating novel
therapies which should have their maximal benefit in situations of
minimal residual disease such as anti-angiogenic agents or
immunotherapy. 
Duration of chemotherapy also needs to be addressed. It has
been shown that 12 months therapy of the optimal regimen is no
better than 6 months (Haller et al, 1998; Wolmark et al, 1999). In
advanced disease, a recent MRC trial showed that 12 weeks of
therapy followed by an interval until disease progression resulted
in improved quality of life with no detriment to overall survival
when compared with continued therapy until progression
(Maughan et al, 2001). Could a similar shortened schedule be
equally effective in adjuvant therapy? Saini and colleagues
reported a trial comparing 12 weeks infusional 5FU versus 6
months 5FU plus folinic acid and reported no detriment in survival
(Saini et al, 2000). A shorter schedule with similar effectiveness
would have great benefits for patients and the economy. 
The major breakthrough will be the ability to define from mole-
cular as well as conventional histopathological criteria, which
patients need chemotherapy and which will benefit from a specific
combination selected from an increasing array of options. At
present data in this area are very confused. Data from a non-
randomised retrospective series suggested that all the benefit from
adjuvant therapy is due to a major improvement in survival in
those patients with tumours expressing high microsatellite insta-
bility (Elsaleh et al, 2000). This attractive idea would give an
excellent scientific rationale for the difficulty in proving benefit in
the rectal subgroup, in whom microsatellite instability occurs in
about 1% compared to 15–20% of colonic cancers. However, it has
not been substantiated in the large prospective randomised series
from the AXIS study which showed no correlation between MSI
status and benefit from chemotherapy (Barrett et al, 2001). It also
flies in the face of laboratory data which suggest that 5FU is a rela-
tively ineffective drug in these tumours, and that the old alkylating
agent CCNU might be the agent of choice (Aguilina et al, 1998). 
The identification of poor prognostic factors can be used to
identify patients likely to gain more from adjuvant therapy.
However, if these factors also result in non-response to
chemotherapy, then that supposed benefit will turn out to be illu-
sory. Such a situation appears to be the case for deletions of 18q.
This was shown to be a poor prognostic factor by Vogelstein’s
group, who also suggested that it would therefore be appropriate to
select these patients for chemotherapy (Jen et al, 1994). However,
one clear message from the AXIS analysis is that loss of 18q and
p53 mutation results in a loss of benefit from chemotherapy
(Barrett et al, 2001). 
The future lies not just in candidate gene analysis but in genetic
profiling of tumours to determine the whole range of genetic aber-
rations present in the individual’s tumour. This massive enterprise
is now entirely feasible though overwhelmingly expensive using
microarray technology. However, there is hope that by measuring
the totality of the genomic variation and correlating that with
response to the increasing diversity of treatment options, we will
be able to identify key factors and pathways which will enable us
to select the very best adjuvant therapy for our colorectal cancer
patients on an individual basis. 
TS Maughan 
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